A combination of N- (3-methoxy-5-methylpyrazin-2-yl)-2-(4-[ 1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-s ulphonamide and an anti-mitotic agent for the treatment of cancer

Details for Australian Patent Application No. 2005308588 (hide)

International Classifications

Event Publications

31 May 2007 PCT application entered the National Phase

PCT publication WO2006/056760 Priority application(s): WO2006/056760

30 July 2009 Amendment Made

The nature of the amendment is: Amend the invention title to read A combination of N- (3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyrid ine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer

29 April 2010 Application Accepted

Published as AU-B-2005308588

26 August 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.